TABLE 2. Evaluation of the correlation between laboratory findings, the mean duration of the updosing phase and OIT onset age of the patients

		OIT onset age of the patients	IgE	CM-sIgE	Wheal diameters CM in SPTs	Cumulative provocative dose in the OFC	The mean duration of the buildup phase (week)
OIT onset age of the patients (month)	**rs**	1.000	0.302	0.076	0.053	0.086	0.187
	p		0.070	0.631	0.739	0.614	0.236
Total IgE (kU/l)	**rs**	0.302	1.000	0.677**	0.265	-0.221	-0.030
	p	0.070		**0.000**	0.113	0.224	0.862
CM-sIgE (kUA/l)	**rs**	0.076	0.677**	1.000	0.436**	-0.091	0.093
	p	0.631	**0.000**		**0.004**	0.591	0.557
Wheal diameters CM in SPTs (mm)	**rs**	0.053	0.265	0.436**	1.000	0.003	0.127
	p	0.739	0.113	**0.004**		0.986	0.423
Cumulative provocative dose in the OFC (mL)	**rs**	0.086	-0.221	-0.091	0.003	1.000	-0.232
	p	0.614	0.224	0.591	0.986		0.168

TABLE 1. Demographic Characteristics and Laboratory Findings

	Results
Patients onset age of the symptoms (month)	5.4±4.6 (1-30)
OIT onset age of the patients (month)	40.2±3.2 (36-156)
Median Total IgE (kU/l)	125 (4-1731)
Median CM-sIgE (kUA/l) (at the start of OIT)	5.8 (0.5-100)
Median wheal diameter to CM in SPT (mm)	8.5 (3-35)
Median cumulative provocative dose of OFC (mL)	6 (0.2-48)
Median peripheral blood eosinophil (%)	3.4 (1-25.7)

TABLE 3. Characteristics of the adverse reactions of the patient

Patient ages, sex distribution (F/M)	The reactive dose of OFC	Reaction doses of adverse reactions	The mean duration of buildup phase (weeks)	Symptoms
37 months, M	0.5 mL	140 mL	25	Lokalized urticaria
36 months, M	48 mL	50 mL 55 mL	12	Localized urticaria Urticaria and angioedema
36 months, M	19 mL	25 mL 30 mL 38 mL	15	Localized erythema, itching of the throat Cough, wheezing, Exacerbation of atopic dermatitis
40 months, M	0.3 mL	0.6 mL 1,5 mL 12 mL	20	Lokalized urticaria Cough, wheezing, Lokalized urticaria
36 months, F	10 mL	15 mL	19	Localized urticaria
38 months, F		6 mL 16 mL	14	Vomiting Localized urticaria
37 months, F	6 mL	5 mL 100 mL	20	Vomiting, refuse to take milk Localized urticaria
38 months, M	3 mL	15 mL 30 mL	20	Exacerbation of atopic dermatitis Localized urticaria
36months, F	2,5 mL	2mL 6 mL	17	Cough, respiratory distres
50 months, F		8 mL 12 mL 15 mL 25 mL 110 mL 130 mL	43	Cough, respiratory distres Localized urticaria, Localized urticaria, Cough and respiratory distres Localized urticaria, Vomiting
43 months, F	1.4 mL	5 mL	20	Localized urticaria, Cough, wheezing, Localized urticaria Vomiting
36 months, F		50 mL	19	
42 months, F	6 mL	12 mL 36 mL	21	Sistemic urticaria Localized urticaria
68 months, F	6 mL	10 mL 25 mL	19	Cough, respiratory distres Erythema,itching in the mouth and throat
36 months, M	6 mL	12 mL 45 mL	18	Localized urticaria Exacerbation of atopic dermatitis
37 months, M		5 mL	19	Localized urticaria

TABLE 4. OIT duration and laboratory findings between the two groups of patients with and without adverse reactions			
Adverse reactions	**No** (n=26)	**Yes** (n=16)	**p**
OIT onset age of the patients (month)	40.9±5.6 (36-156)	40.3±8 (36-68)	p=0.26
The mean duration of buildup phase (weeks)	15.5±3.3 (9-24)	21.4±8.6 (12-43)	**p=0.001**
The mean duration of the maintenance phase (weeks)	25.8±5.1 (12-39)	26.8±6.7 (13-37)	p=0.82
Median Total IgE (kU/l) (at the beginning of OIT)	125 (4-1731)	118 (9.9-2142)	p=0.83
Median CM-sIgE (kUA/l) (at the beginning of OIT)	4,2 (0.5-75.7)	11.9 (1.9-100)	p=0.17
Median CM-sIgE (kUA/l) (at the end of the updosing phase)	3.8 (0-63.7)	5.6 (0.2-72.2)	p=0.288
Median CM-sIgE (kUA/l) (6 months of maintenance phase)	2 (0-43.2)	2.1 (0.1-72.2)	p=0.445
Median CM-sIgE (kUA/l) (1 year of maintenance phase)	0.8 (0-16.5)	1.3 (0-75.7)	p=0.487
Median CM-sIgE (kUA/l) (2 years of maintenance phase)	0.4 (0-9.8)	0.8 (0-60.8)	p=0.168
Median CM-sIgE (kUA/l) (3 years of maintenance phase)	0.4 (0.4-0.4)	0.1 (0-0,2)	***
Wheal diameters to CM in SPT (mm)	6.5 (0-20)	9.5 (0-35)	**p=0.035**
Median peripheral blood eosinophil (%) (at the beginning of OIT)	4.3 (0.9-25.7)	1.9 (0-8.5)	p=0.082
Median peripheral blood eosinophil (%) (at the end of the updosing phase)	3.7 (0.9-15.1)	3.7 (1.4-10.6)	p=0.841
Median cumulative provocative dose of OFC (mL)	4.5 (0.2-48)	6 (0.3-48)	p=0.783

TABLE 5. Patient characteristics according to the history of anaphylaxis			
	History of anaphylaxis (no) (n:35)	**History of anaphylaxis (yes)** (n=7)	**p**
Median Total IgE kU/l) (at the beginning of OIT)	76 (4-1461)	305 (53-2142)	**0.02**
Median CM-sIgE values (kUA/l) (at the beginning of OIT)	4.3 (2-75)	51(3-106)	**0.006**
Median wheal diameters to CM in SPT (mm) (at the beginning of OIT)	7 (3-20)	15 (9-35)	**0.001**
The mean duration of buildup phase (weeks)	16.8± 3.2 (10-25)	22±14 (13-41)	**0.04**
Median cumulative provocative doses of OFC (mL)	0.85 (0.3-1.4)	6 (0.2-48)	0.06
Adverse reactions during OIT (yes)	31.4% (n=11)	71.4% (n=5)	**0.04**
Number of reactions during OIT	0 (0-3)	2 (0-6)	**0.01**

Step	Time	Place	Time	Place	Dose (mL) (milligram protein)
1	1th day	*Hospital*	2-7th day	*Home*	0.05 mL (1.65 mg)
2	8th day	*Hospital*	9-14th day	*Home*	0.1 mL (3.3 mg)
3	15th day	*Hospital*	16-21th day	*Home*	0.3 mL (9.9 mg)
4	22th day	*Hospital*	23-28th day	*Home*	0.6 mL (19.8 mg)
5	29th day	*Hospital*	30-35th day	*Home*	0.8 mL (26.4 mg)
6	36th day	*Hospital*	37-42th day	*Home*	0.9 mL (29.7 mg)
7	43th day	*Hospital*	44-49th day	*Home*	1 mL (33 mg)
8	50th day	*Hospital*	51-56th day	*Home*	2 mL (66 mg)
9	57th day	*Hospital*	58-63th day	*Home*	5 mL (165 mg)
10	64th day	*Hospital*	65-70th day	*Home*	8 mL (264 mg)
11	71th day	*Hospital*	72-77th day	*Home*	12 mL (396 mg)
12	78th day	*Hospital*	79-84 th day	*Home*	15 mL (495 mg)
13	85th day	*Hospital*	86-91th day	*Home*	20 mL (660 mg)
14	92th day	*Hospital*	93-98th day	*Home*	25 mL (825 mg)
15	99th day	*Hospital*	100-105th day	*Home*	35 mL (1155 mg)
16	106th day	*Hospital*	107-112th day	*Home*	45 mL (1485 mg)
17	113th day	*Hospital*	114-119th day	*Home*	60 mL (1980 mg)
18	120th day	*Hospital*	121-126th day	*Home*	75 mL (2475 mg)
19	127th day	*Hospital*	128-133th day	*Home*	90 mL (2970 mg)
20	134th day	*Hospital*	135-140th day	*Home*	110 mL (3630 mg)
21	141th day	*Hospital*	142-147th day	*Home*	130 mL (4290 mg)
22	148th day	*Hospital*	149-154th day	*Home*	150 mL (4950 mg)
23	155th day	*Hospital*	156-161th day	*Home*	170 mL (5610 mg)
24	162th day	*Hospital*	163-168th day	*Home*	190 mL (6270 mg)
25	169th day	*Hospital*	170-175th day	*Home*	200 mL (6540 mg)

FIG. 1. Oral immunotherapy protocol for cow's milk.



FIG. 2. Wheal diameters (mm) to cow's milk (commercial extract) in skin prick test.



FIG. 3. The median CM-sIgE level (kUA/l) results in three years follow-up OIT.